Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer

Area of Science:

• Oncology
• Genomics
• Cancer Research

Background:

• Metastatic colorectal cancer (mCRC) management relies on comprehensive genomic profiling.
• The clinical significance of PIK3CA mutations, found in up to 20% of mCRCs, remains unclear.
• Understanding PIK3CA mutation impact is crucial for optimizing mCRC treatment strategies.

Purpose of the Study:

• To investigate the associations between PIK3CA mutations and other common mutations in mCRC.
• To determine the prognostic value of PIK3CA mutations in mCRC patients.
• To evaluate the predictive value of PIK3CA mutations regarding response to anti-EGFR therapy.

Main Methods:

• Retrospective analysis of mCRC patients from the Moffitt Clinical Genomic Database.
• Correlation analysis of PIK3CA mutations with KRAS, TP53, and ERBB2 alterations.
• Meta-analysis of PIK3CA mutation impact on anti-EGFR therapy response across 12 studies.

Main Results:

• PIK3CA mutations correlated positively with KRAS and negatively with TP53 mutations and ERBB2 amplification.
• Patients with PIK3CA-mutant mCRC had significantly shorter overall survival (OS) compared to wild-type.
• Meta-analysis revealed PIK3CA mutations predict reduced response to anti-EGFR therapy (RR 0.56).

Conclusions:

• PIK3CA mutations are identified as a poor prognostic factor in mCRC.
• PIK3CA mutations predict a diminished response to anti-EGFR therapies in mCRC.
• Genomic insights into PIK3CA are vital for refining mCRC treatment paradigms.